title: How dangerous are norovirus infections in patients with rheumatic diseases treated with biologics and DMARDs? Follow-up on a local outbreak and comparison with a control cohort.
authors.affiliation: ACURA Center for Rheumatic Diseases, , Baden-Baden, Germany.
authors.forename: Christoph
authors.initials: C
authors.lastname: Fiehn
authors.forename: Nikolaus
authors.initials: N
authors.lastname: Miehle
mesh_terms: D000368:Aged; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001688:Biological Products / Q000009:adverse effects*; D017250:Caliciviridae Infections / Q000276:immunology*; D016022:Case-Control Studies; D003428:Cross Infection / Q000276:immunology; D004196:Disease Outbreaks; D005500:Follow-Up Studies; D005759:Gastroenteritis / Q000276:immunology; D006801:Humans; D016867:Immunocompromised Host; D008875:Middle Aged; D029322:Norovirus / Q000472:pathogenicity*; D012216:Rheumatic Diseases / Q000188:drug therapy*
chemical_list: D018501:Antirheumatic Agents; D001688:Biological Products
keywords: Corticosteroids; DMARDs (biologic); DMARDs (synthetic); Infections; Methotrexate